Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Hydrochloric Acid | HCID 313 | — |
| Reactant | Piperazine | HCID 4837 | — |
| Reactant | HCID 25054550 | HCID 25054550 | — |
| Product | HCID 68458635 | HCID 68458635 | 18% |
Reaction Steps
Following the procedure of Example 27 (step b), but substituting 2-oxa-5-azabicyclo[2.2.1]heptane for piperazine, 1-(1-(2-(2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)ethyl)-1H-indazol-5-yl)-4-(benzyloxy)pyridin-2(1H)-one was prepared as a yellow powder: 1H NMR (500 MHz, DMSO-d6) δ 8.02 (s, 1H), 7.66 (d, J=1.6 Hz, 1H), 7.51 (d, J=8.9 Hz, 1H), 7.44-7.35 (m, 6H), 7.29 (d, J=7.4 Hz, 1H), 6.10-6.05 (m, 2H), 5.06 (s, 2H), 4.48 (t, J=6.9 Hz, 2H), 4.36 (s, 1H), 3.95 (d, J=7.8 Hz, 1H), 3.59 (dd, J=7.6, 1.7 Hz, 1H), 3.40 (s, 1H), 3.15-3.05 (m, 1H), 2.88 (dd, J=9.9, 1.6 Hz, 1H) 2.53 (d, J=9.8 Hz, 1H), 1.80-1.74 (m, 2H), 1.72-1.67 (m, 1H); ESI MS m/z 443 [M+H]+This was converted to the HCl salt to give the title compound (17.4 mg, 18%) as a yellow powder: ESI MS m/z 443 [M+H]+.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08268868B2 |
|---|
| Source dataset | uspto-grants-2012_09 |
|---|
| ORD ID | ord-77571f5f9d894505b07887827b68a2fb |
|---|
| Source note | uspto-grants-2012_09 |
|---|